Jun 03, 2020
Zeulide Depot(TM) is now Covered by the Ontario Drug Benefit (ODB) Program for Patients Living with Prostate Cancer
Mar 29, 2019
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg
Mar 05, 2019
Enteris BioPharma Supports Endometriosis Awareness Month
Feb 21, 2019
Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer
Feb 11, 2019
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Nov 26, 2018
Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer
Oct 24, 2018
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
Oct 05, 2018
Tolmar Pharmaceuticals Sponsors 2018 ZERO - The End of Prostate Cancer Endurance Team at the Bank of America Chicago Marathon
Jun 26, 2018
Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
Mar 15, 2018
Enteris BioPharma to Present at the 25th Annual Future Leaders in the Biotech Industry Conference
Mar 01, 2018
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA(TM)
Feb 13, 2018
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
Nov 09, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids
Oct 02, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids